Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis

被引：0
|
作者：
Mease, Philip [1 ]
Smolen, Josef [2 ]
Kavanaugh, Arthur [3 ]
Nash, Peter [4 ]
Gallo, Gaia [5 ]
Liu-Leage, Soyi [5 ]
Sapin, Christophe [5 ]
Genovese, Mark [6 ]
Bessette, Louis [7 ]
机构：
[1] Univ Washington, Seattle, WA USA
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Univ Queensland, Brisbane, Qld, Australia
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Stanford Univ, Palo Alto, CA 94304 USA
[7] Laval Univ, Quebec City, PQ, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
125
引用
收藏
页码：1167 / 1167
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naive Patients with Psoriatic Arthritis: 52-Week Results
    Smolen, Josef
    Sebba, Anthony
    Ruderman, Eric
    Gellett, Amanda
    Sapin, Christophe
    Sprabery, Aubrey
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Reis, Paulo
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [32] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
    Smolen, Josef S.
    Burmester, Gerd-Ruediger
    Combe, Bernard
    Curtis, Jeffrey R.
    Hall, Stephen
    Haraoui, Boulos
    van Vollenhoven, Ronald
    Cioffi, Christopher
    Ecoffet, Cecile
    Gervitz, Leon
    Ionescu, Lucian
    Peterson, Luke
    Fleischmann, Roy
    LANCET, 2016, 388 (10061): : 2763 - 2774
  • [33] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [34] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) (vol 45, pg 367, 2018)
    Van der Heijde, D.
    Gladman, D. D.
    Kishimoto, M.
    Okada, M.
    Rathmann, S. S.
    Moriarty, S. R.
    Shuler, C. L.
    Carlier, H.
    Benichou, O.
    Mease, P. J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (11) : 1608 - 1608
  • [35] MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS
    Mease, Philip J.
    Smolen, Josef S.
    Behrens, Frank
    Nash, Peter
    Leage, Soyi Liu
    Li Lingnan
    Tahir, Hasan
    Gooderham, Melinda
    Krishnan, Eswar
    Emery, Paul
    Pillai, Sreekumar
    Helliwell, Philip
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 261 - 262
  • [36] Efficacy of ixekizumab vs. adalimumab in patients with psoriatic arthritis with moderate-to-severe psoriasis: 52-week results from a multicentre, randomized, open-label study
    Kleyn, C. E.
    Gooderham, M.
    Kristensen, L. E.
    de Vlam, K.
    Schuster, C.
    Leage, S. Liu
    McKenzie, R.
    Sapin, C.
    Li, L.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 70 - 71
  • [37] Head-to-head trial shows abatacept is as effective as adalimumab in patients with active rheumatoid arthritis
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (08) : 431 - 431
  • [38] HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VS ADALIMUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: KEY EFFICACY AND SAFETY RESULTS FROM THE AMPLE TRIAL
    Weinblatt, Michael E.
    Schiff, Michael H.
    Fleischmann, Roy
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Zhao, Cathy
    Maldonado, Michael A.
    RHEUMATOLOGY, 2013, 52 : 45 - 46
  • [39] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 24 IN BIOLOGIC EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SUMMARY RESULTS
    Marzo-Ortega, Helena
    Meroni, Pierluigi
    Galindez-Agirregoikoa, Eva
    Behrens, Frank
    Bradley, Andrew J.
    Leage, Soyi Liu
    Garcia, Miriam
    Sapin, Christophe
    Ho, Ji Chen
    Constantin, Arnaud
    Hall, Stephen
    RHEUMATOLOGY, 2018, 57
  • [40] SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
    Mcinnes, I.
    Behrens, F.
    Mease, P. J.
    Kavanaugh, A.
    Ritchlin, C. T.
    Nash, P.
    Gratacos-Masmitja, J.
    Goupille, P.
    Korotaeva, T.
    Gottlieb, A. B.
    Martin, R.
    Ding, K.
    Pellet, P.
    Mpofu, S.
    Pricop, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 142 - 143
12345